This week on Capitol Hill, the heated drug pricing debate is back in the spotlight, with a Senate Judiciary Committee hearing on intellectual property and the price of prescription drugs on Tuesday. In the House of Representatives, oversight hearings will examine both the activities of the U.S. Patent and Trademark Office and data security efforts made by the Federal Trade Commission. Off the Hill, The Cato Institute looks at U.S. cyber defense capabilities, and the week closes with a Brookings Institution event on China’s actions towards global tech dominance.
This Week on Capitol Hill: Senate Examines Effect of IP on Drug Prices Again, House IP Subcommittee Talks USPTO Oversight
No Comments
Patent
- Enablement
- Fee Shifting
- Litigation
- Other Barks & Bites for Friday, January 22: Iancu and Peter Step Down from USPTO, CJEU Asked Whether Preliminary Injunction Standard Burdens Patent Owners, SCOTUS Denial Leaves Invalidation of Idenix Genus Patent Claims Untouched
- US Inventor Backs SCOTUS Petition to Clarify Claim Construction Principles
- Iancu Says Goodbye, Urges Commitment to ‘American Innovation Renaissance’
- Biden’s Opportunity to Protect American Innovation
- Washington Insiders Say Farewell to 2020 and Look Ahead to 2021
Recent Posts
- Other Barks & Bites for Friday, January 22: Iancu and Peter Step Down from USPTO, CJEU Asked Whether Preliminary Injunction Standard Burdens Patent Owners, SCOTUS Denial Leaves Invalidation of Idenix Genus Patent Claims Untouched
- US Inventor Backs SCOTUS Petition to Clarify Claim Construction Principles
- Iancu Says Goodbye, Urges Commitment to ‘American Innovation Renaissance’
- Biden’s Opportunity to Protect American Innovation
- Washington Insiders Say Farewell to 2020 and Look Ahead to 2021